MCID: PRM293
MIFTS: 42

Primary Mediastinal B-Cell Lymphoma

Categories: Blood diseases, Cancer diseases, Immune diseases, Rare diseases

Aliases & Classifications for Primary Mediastinal B-Cell Lymphoma

MalaCards integrated aliases for Primary Mediastinal B-Cell Lymphoma:

Name: Primary Mediastinal B-Cell Lymphoma 12 15
Mediastinal Diffuse Large-Cell Lymphoma with Sclerosis 12
Primary Mediastinal Clear Cell Lymphoma of B-Cell Type 12
Large Cell Lymphoma of the Mediastinum 12

Classifications:



External Ids:

Disease Ontology 12 DOID:0080210
ICD10 33 C85.2

Summaries for Primary Mediastinal B-Cell Lymphoma

Disease Ontology : 12 A diffuse large B-cell lymphoma that is is characterized by a diffuse proliferation of medium to large B-cells associated with sclerosis.

MalaCards based summary : Primary Mediastinal B-Cell Lymphoma, also known as mediastinal diffuse large-cell lymphoma with sclerosis, is related to primary mediastinal large b-cell lymphoma and b-cell lymphomas. An important gene associated with Primary Mediastinal B-Cell Lymphoma is BCL6 (BCL6, Transcription Repressor), and among its related pathways/superpathways are TNFR1 Pathway and 4-1BB Pathway. The drugs Vincristine and Lenalidomide have been mentioned in the context of this disorder. Affiliated tissues include b cells and t cells, and related phenotypes are cellular and hematopoietic system

Related Diseases for Primary Mediastinal B-Cell Lymphoma

Graphical network of the top 20 diseases related to Primary Mediastinal B-Cell Lymphoma:



Diseases related to Primary Mediastinal B-Cell Lymphoma

Symptoms & Phenotypes for Primary Mediastinal B-Cell Lymphoma

MGI Mouse Phenotypes related to Primary Mediastinal B-Cell Lymphoma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.13 AICDA BCL11A BCL6 KRAS NFKBIE REL
2 hematopoietic system MP:0005397 10.09 AICDA BCL11A BCL6 KRAS NFKBIE REL
3 immune system MP:0005387 10.02 AICDA BCL11A BCL6 KRAS NFKBIE REL
4 homeostasis/metabolism MP:0005376 10.01 BCL11A BCL6 KRAS PTPN1 REL SPI1
5 endocrine/exocrine gland MP:0005379 10 BCL11A BCL6 KRAS PTPN1 SPI1 STAT6
6 mortality/aging MP:0010768 9.96 AICDA BCL11A BCL6 KRAS NFKBIE PTPN1
7 liver/biliary system MP:0005370 9.8 BCL6 KRAS REL SPI1 STAT6 TNFAIP3
8 no phenotypic analysis MP:0003012 9.55 AICDA BCL6 KRAS SPI1 TNFAIP3
9 respiratory system MP:0005388 9.35 BCL6 KRAS REL STAT6 TNFAIP3
10 skeleton MP:0005390 9.1 KRAS NFKBIE PTPN1 REL SPI1 TNFAIP3

Drugs & Therapeutics for Primary Mediastinal B-Cell Lymphoma

Drugs for Primary Mediastinal B-Cell Lymphoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 77)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Vincristine Approved, Investigational Phase 1, Phase 2,Phase 2,Not Applicable,Early Phase 1 57-22-7, 2068-78-2 5978
2
Lenalidomide Approved Phase 1, Phase 2 191732-72-6 216326
3
Cyclophosphamide Approved, Investigational Phase 1, Phase 2,Phase 2,Not Applicable,Early Phase 1 6055-19-2, 50-18-0 2907
4
Prednisone Approved, Vet_approved Phase 1, Phase 2,Phase 2,Not Applicable,Early Phase 1 53-03-2 5865
5
rituximab Approved Phase 1, Phase 2,Phase 2,Not Applicable,Early Phase 1 174722-31-7 10201696
6
Doxorubicin Approved, Investigational Phase 1, Phase 2,Phase 2,Not Applicable,Early Phase 1 23214-92-8 31703
7
Etoposide Approved Phase 1, Phase 2,Phase 2,Not Applicable,Early Phase 1 33419-42-0 36462
8
Methylprednisolone hemisuccinate Approved Phase 2,Not Applicable 2921-57-5
9
Methylprednisolone Approved, Vet_approved Phase 2,Not Applicable 83-43-2 6741
10
Cytarabine Approved, Investigational Phase 2,Not Applicable 147-94-4 6253
11
Prednisolone Approved, Vet_approved Phase 2,Not Applicable 50-24-8 5755
12
Lenograstim Approved, Investigational Phase 2,Not Applicable 135968-09-1
13
Prednisolone phosphate Approved, Vet_approved Phase 2,Not Applicable 302-25-0
14
Mechlorethamine Approved, Investigational Phase 2,Not Applicable 51-75-2 4033
15
Ifosfamide Approved Phase 2,Not Applicable 3778-73-2 3690
16
Methotrexate Approved Phase 2,Not Applicable,Early Phase 1 59-05-2, 1959-05-2 126941
17
leucovorin Approved Phase 2,Not Applicable,Early Phase 1 58-05-9 6006 143
18
Melphalan Approved Phase 2 148-82-3 4053 460612
19
Cisplatin Approved Phase 2 15663-27-1 2767 441203 84093
20
Pembrolizumab Approved Phase 2,Phase 1 1374853-91-4
21
Fludarabine Approved Phase 1, Phase 2,Phase 2 75607-67-9, 21679-14-1 30751
22
Dexamethasone Approved, Investigational, Vet_approved Phase 2 50-02-2 5743
23
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 2 1177-87-3
24
Carboplatin Approved Phase 2 41575-94-4 10339178 38904 498142
25
Obinutuzumab Approved, Investigational Phase 2 949142-50-1
26
Vidarabine Approved, Investigational Phase 1, Phase 2 24356-66-9 32326 21704
27
Nivolumab Approved Phase 2 946414-94-4
28
Doxil Approved June 1999 Phase 1, Phase 2,Phase 2,Not Applicable,Early Phase 1 31703
29
Prednisolone hemisuccinate Experimental Phase 2,Not Applicable 2920-86-7
30 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 1, Phase 2,Phase 2,Not Applicable,Early Phase 1
31 Antirheumatic Agents Phase 1, Phase 2,Phase 2,Not Applicable,Early Phase 1
32 Hormones Phase 1, Phase 2,Phase 2,Not Applicable,Early Phase 1
33 Immunosuppressive Agents Phase 1, Phase 2,Phase 2,Not Applicable,Early Phase 1
34 Hormone Antagonists Phase 1, Phase 2,Phase 2,Not Applicable,Early Phase 1
35 Topoisomerase Inhibitors Phase 1, Phase 2,Phase 2,Not Applicable,Early Phase 1
36 Antibiotics, Antitubercular Phase 1, Phase 2,Not Applicable,Early Phase 1
37 Angiogenesis Modulating Agents Phase 1, Phase 2
38 Immunologic Factors Phase 1, Phase 2,Phase 2,Not Applicable,Early Phase 1
39 Anti-Infective Agents Phase 1, Phase 2,Phase 2,Not Applicable
40 Antineoplastic Agents, Alkylating Phase 1, Phase 2,Phase 2,Not Applicable,Early Phase 1
41 Etoposide phosphate Phase 1, Phase 2,Phase 2,Not Applicable,Early Phase 1
42 Antineoplastic Agents, Hormonal Phase 1, Phase 2,Not Applicable,Early Phase 1
43 Anti-Bacterial Agents Phase 1, Phase 2,Not Applicable,Early Phase 1
44 Antimitotic Agents Phase 1, Phase 2,Not Applicable,Early Phase 1
45 Anti-Inflammatory Agents Phase 1, Phase 2,Phase 2,Not Applicable,Early Phase 1
46 Alkylating Agents Phase 1, Phase 2,Phase 2,Not Applicable,Early Phase 1
47 Antineoplastic Agents, Phytogenic Phase 1, Phase 2,Phase 2,Not Applicable,Early Phase 1
48 glucocorticoids Phase 1, Phase 2,Phase 2,Not Applicable,Early Phase 1
49 Angiogenesis Inhibitors Phase 1, Phase 2
50 Protective Agents Phase 2,Not Applicable

Interventional clinical trials:

(show all 19)
# Name Status NCT ID Phase Drugs
1 Ibrutinib and Lenalidomide With Dose Adjusted EPOCH-R in Subjects With Relapsed/Refractory Diffuse Large B-cell Lymphoma Unknown status NCT02142049 Phase 1, Phase 2 Ibrutinib;Part 1: Dose Level 1
2 R-MegaCHOP-ESHAP-BEAM in Patients With High-Risk Aggressive B-Cell Lymphomas Completed NCT00558220 Phase 2
3 Study of Ibrutinib in Combination With Bendamustine and Rituximab for Patients With Relapsed/Refractory Aggressive BCL Recruiting NCT02747732 Phase 2 Bendamustine 90 mg/m2 IV on Days 1-2, Cycles 1-6
4 Pembrolizumab and Fractionated External Beam Radiotherapy (EBRT) in Patients With Non-Hodgkin Lymphoma (NHL) Recruiting NCT03210662 Phase 2 Pembrolizumab
5 Safety and Efficacy of KTE-C19 in Adults With Refractory Aggressive Non-Hodgkin Lymphoma Recruiting NCT02348216 Phase 1, Phase 2 Fludarabine;Cyclophosphamide
6 Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL Recruiting NCT02393157 Phase 2 Obinutuzumab;Liposomal ARA-C;Ifosfamide;Carboplatin;Etoposide
7 Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Previously Untreated Aggressive Non-Hodgkin's Lymphoma Recruiting NCT00001337 Phase 2 EPOCH
8 Treatment for Advanced B-Cell Lymphoma Recruiting NCT01859819 Phase 2 Rituximab;IT Cytarabine
9 CAR T Cell Receptor Immunotherapy for Patients With B-cell Lymphoma Active, not recruiting NCT00924326 Phase 1, Phase 2 Fludarabine;Cyclophosphamide
10 Copanlisib and Nivolumab in Treating Participants With Recurrent or Refractory Diffuse Large B-cell Lymphoma or Primary Mediastinal Large B-cell Lymphoma Not yet recruiting NCT03484819 Phase 2 Copanlisib
11 T Cells Expressing a Fully-Human Anti-CD30 Chimeric Antigen Receptor for Treating CD30-Expressing Lymphomas Recruiting NCT03049449 Phase 1 Cyclophosphamide;Fludarabine
12 Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (TRANSCEND-NHL-001) Recruiting NCT02631044 Phase 1
13 A Trial of Pembrolizumab (MK-3475) in Participants With Blood Cancers (MK-3475-013/KEYNOTE-013) Active, not recruiting NCT01953692 Phase 1 Lenalidomide
14 Combination Chemotherapy and Rituximab in Treating Patients With Primary Mediastinal Diffuse Large B-Cell Lymphoma Unknown status NCT00689845 Not Applicable cyclophosphamide;cytarabine;doxorubicin hydrochloride;etoposide phosphate;ifosfamide;methotrexate;prednisolone;prednisone;vincristine sulfate;vindesine
15 A Clinico-Pathologic Study of Primary Mediastinal B-Cell Lymphoma Completed NCT00944567
16 Mediastinal Grey Zone Lymphoma From the LYSA Completed NCT03037177
17 Dose Adjusted EPOCH-R, to Treat Mature B Cell Malignancies Completed NCT01760226 Early Phase 1 DA-EPOCH-R for DLBCL, PTLD, AND PMBCL;Methotrexate;Etoposide;Doxorubicin;Vincristine;Rituximab;Cyclophosphamide;Prednisone;G-CSF
18 Randomized, Open-label, Two-arms, Phase III Comparative Study Assessing the Role of Involved Mediastinal Radiotherapy After Rituximab Containing Chemotherapy Regimens to Patients With Newly Diagnosed Primary Mediastinal Large B-Cell Lymphoma Recruiting NCT01599559 Not Applicable
19 Axicabtagene Ciloleucel Expanded Access Study Available NCT03153462

Search NIH Clinical Center for Primary Mediastinal B-Cell Lymphoma

Genetic Tests for Primary Mediastinal B-Cell Lymphoma

Anatomical Context for Primary Mediastinal B-Cell Lymphoma

MalaCards organs/tissues related to Primary Mediastinal B-Cell Lymphoma:

41
B Cells, T Cells

Publications for Primary Mediastinal B-Cell Lymphoma

Articles related to Primary Mediastinal B-Cell Lymphoma:

(show top 50) (show all 100)
# Title Authors Year
1
Autologous stem cell transplantation for primary mediastinal B-cell lymphoma: long-term outcome and role of post-transplant radiotherapy. A report of the European Society for Blood and Marrow Transplantation. ( 29463854 )
2018
2
End-of-treatment and serial PET imaging in primary mediastinal B-cell lymphoma following dose-adjusted-EPOCH-R: A paradigm shift in clinical decision making. ( 29748435 )
2018
3
Metabolic heterogeneity on baseline 18FDG-PET/CT scan is a predictor of outcome in primary mediastinal B-cell lymphoma. ( 29720487 )
2018
4
What is the standard of care for primary mediastinal B cell lymphoma; R-CHOP or DA-EPOCH-R? - Response to Melani etA al. ( 29528099 )
2018
5
STAT6 is a cargo of exportin 1: Biological relevance in primary mediastinal B-cell lymphoma. ( 29501729 )
2018
6
Lactate dehydrogenase levels and 18F-FDG PET/CT metrics differentiate between mediastinal Hodgkin's lymphoma and primary mediastinal B-cell lymphoma. ( 29672465 )
2018
7
Ruxolitinib significantly enhances <i>in vitro</i> apoptosis in Hodgkin lymphoma and primary mediastinal B-cell lymphoma and survival in a lymphoma xenograft murine model. ( 29515770 )
2018
8
A study of the dosimetric characteristics between different fixed-field IMRT and VMAT in early-stage primary mediastinal B-cell lymphoma. ( 28935521 )
2018
9
Management of Primary Mediastinal B-Cell Lymphoma in Pregnancy. ( 29686956 )
2018
10
R-CHOP versus dose-adjusted R-EPOCH in frontline management of primary mediastinal B-cell lymphoma: a multi-centre analysis. ( 29265182 )
2018
11
What is the standard of care for primary mediastinal b-cell lymphoma; R-CHOP or DA-EPOCH-R? ( 29532904 )
2018
12
How I treat primary mediastinal B-cell lymphoma. ( 29976557 )
2018
13
Combined PD-1 and JAK1/2 inhibition in refractory primary mediastinal B-cell lymphoma. ( 29327077 )
2018
14
HLA genotype and response to nivolumab therapy in relapsed refractory primary mediastinal B-cell lymphoma. ( 30448276 )
2018
15
The unique biology and treatment of primary mediastinal B-cell lymphoma. ( 30213393 )
2018
16
Ten Things to Know About Primary Mediastinal B Cell Lymphoma. ( 30244100 )
2018
17
Utilizing multiple pathway cross-talk networks reveals hub pathways in primary mediastinal B-cell lymphoma. ( 30249889 )
2018
18
Unproven value of end-of-treatment and serial follow-up FDG-PET in primary mediastinal B-cell lymphoma. ( 30065019 )
2018
19
End-of-treatment and serial PET imaging has prognostic value and clinical utility in primary mediastinal B-cell lymphoma following dose-adjusted EPOCH-R - Response to Adams et al. ( 30065020 )
2018
20
Outcomes of adults and children with primary mediastinal B-cell lymphoma treated with dose-adjusted EPOCH-R. ( 29082519 )
2017
21
Second cancer incidence in primary mediastinal B-cell lymphoma treated with methotrexate with leucovorin rescue, doxorubicin, cyclophosphamide, vincristine, prednisone, and bleomycin regimen with or without rituximab and mediastinal radiotherapy: Results from a monoinstitutional cohort analysis of long-term survivors. ( 28078727 )
2017
22
High-grade neutropenia in a patient successfully treated with nivolumab for refractory primary mediastinal B-cell lymphoma. ( 29296772 )
2017
23
Primary mediastinal B-cell lymphoma: biology and evolving therapeutic strategies. ( 29222270 )
2017
24
Addition of rituximab to CHOP-like chemotherapy in first line treatment of primary mediastinal B-cell lymphoma. ( 28532396 )
2017
25
Management of Primary Mediastinal B-Cell Lymphoma and Gray Zone Lymphoma. ( 28620906 )
2017
26
Training improves the interobserver agreement of the expert positron emission tomography review panel in primary mediastinal B-cell lymphoma: interim analysis in the ongoing International Extranodal Lymphoma Study Group-37 study. ( 27545416 )
2017
27
Positron Emission Tomography/Computed Tomography Assessment After Immunochemotherapy and Irradiation Using the Lugano Classification Criteria in the IELSG-26 Study of Primary Mediastinal B-Cell Lymphoma. ( 27839910 )
2017
28
Recurrent mutations of the exportin 1 gene (XPO1) and their impact on selective inhibitor of nuclear export compounds sensitivity in primary mediastinal B-cell lymphoma. ( 27312795 )
2016
29
Frequent NFKBIE deletions are associated with poor outcome in primary mediastinal B-cell lymphoma. ( 27670424 )
2016
30
Optimizing Outcomes in Primary Mediastinal B-cell Lymphoma. ( 27888880 )
2016
31
Mediastinal Gray Zone Lymphoma with Features Intermediate between Classical Hodgkin Lymphoma and Primary Mediastinal B-Cell Lymphoma. ( 27623181 )
2016
32
Improved Survival With Radiation Therapy in Stage I-II Primary Mediastinal B Cell Lymphoma: A Surveillance, Epidemiology, and End Results Database Analysis. ( 26547384 )
2016
33
Improved survival with combined modality therapy in the modern era for primary mediastinal B-cell lymphoma. ( 26852276 )
2016
34
Extranodal diffuse large B-cell lymphoma (DLBCL) and primary mediastinal B-cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. ( 27377716 )
2016
35
Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) in the management of primary mediastinal B-cell lymphoma: a subgroup analysis of the UK NCRI R-CHOP 14 versus 21 trial. ( 27477167 )
2016
36
Primary mediastinal B-cell lymphoma - metabolic and anatomical features in 18FDG-PET/CT and response to therapy. ( 27688726 )
2016
37
Primary mediastinal B-cell lymphoma and mediastinal gray zone lymphoma: do they require a unique therapeutic approach? ( 25499450 )
2015
38
The utility and limitations of (18)F-fluorodeoxyglucose positron emission tomography with computed tomography in patients with primary mediastinal B-cell lymphoma: single institution experience and literature review. ( 24724780 )
2015
39
The role of FDG-PET imaging as a prognostic marker of outcome in primary mediastinal B-cell lymphoma. ( 25205600 )
2015
40
Single-institution experience in the treatment of primary mediastinal B cell lymphoma treated with immunochemotherapy in the setting of response assessment by 18fluorodeoxyglucose positron emission tomography. ( 25863759 )
2015
41
Interobserver variability in clinical target volume delineation for primary mediastinal B-cell lymphoma. ( 26547826 )
2015
42
Genomic Landscape of Primary Mediastinal B-Cell Lymphoma Cell Lines. ( 26599546 )
2015
43
Absence of BRAF and KRAS hotspot mutations in primary mediastinal B-cell lymphoma. ( 24397598 )
2014
44
KIT mutations in primary mediastinal B-cell lymphoma. ( 25148223 )
2014
45
FOXO1 downregulation contributes to the oncogenic program of primary mediastinal B-cell lymphoma. ( 24977668 )
2014
46
Recurrent somatic mutations of PTPN1 in primary mediastinal B cell lymphoma and Hodgkin lymphoma. ( 24531327 )
2014
47
Treatment of primary mediastinal B-cell lymphoma with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone is associated with a high rate of primary refractory disease. ( 23734654 )
2014
48
A unique case of refractory primary mediastinal B-cell lymphoma with JAK3 mutation and the role for targeted therapy. ( 24837469 )
2014
49
Targeting primary mediastinal B-cell lymphoma. ( 25138048 )
2014
50
STAT6-mediated BCL6 repression in primary mediastinal B-cell lymphoma (PMBL). ( 23852366 )
2013

Variations for Primary Mediastinal B-Cell Lymphoma

Cosmic variations for Primary Mediastinal B-Cell Lymphoma:

9 (show top 50) (show all 79)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM96797 XPO1 haematopoietic and lymphoid tissue,mediastinum,lymphoid neoplasm,primary mediastinal B cell lymphoma c.1711G>A p.E571K 2:61492337-61492337 3
2 COSM45892 TP53 haematopoietic and lymphoid tissue,mediastinum,lymphoid neoplasm,primary mediastinal B cell lymphoma c.857A>C p.E286A 17:7673763-7673763 3
3 COSM45652 TP53 haematopoietic and lymphoid tissue,mediastinum,lymphoid neoplasm,primary mediastinal B cell lymphoma c.914A>C p.K305T 17:7673706-7673706 3
4 COSM35925 TNFAIP3 haematopoietic and lymphoid tissue,mediastinum,lymphoid neoplasm,primary mediastinal B cell lymphoma c.1004T>G p.L335* 6:137878449-137878449 3
5 COSM35928 TNFAIP3 haematopoietic and lymphoid tissue,mediastinum,lymphoid neoplasm,primary mediastinal B cell lymphoma c.2343A>T p.E781D 6:137881289-137881289 3
6 COSM35930 TNFAIP3 haematopoietic and lymphoid tissue,mediastinum,lymphoid neoplasm,primary mediastinal B cell lymphoma c.569C>A p.S190* 6:137875770-137875770 3
7 COSM6932498 SOX17 haematopoietic and lymphoid tissue,mediastinum,lymphoid neoplasm,primary mediastinal B cell lymphoma c.146C>T p.P49L 8:54458284-54458284 3
8 COSM6986928 SOCS1 haematopoietic and lymphoid tissue,mediastinum,lymphoid neoplasm,primary mediastinal B cell lymphoma c.182A>T p.H61L 16:11255297-11255297 3
9 COSM6986927 SOCS1 haematopoietic and lymphoid tissue,mediastinum,lymphoid neoplasm,primary mediastinal B cell lymphoma c.533G>A p.C178Y 16:11254946-11254946 3
10 COSM6932501 SOCS1 haematopoietic and lymphoid tissue,mediastinum,lymphoid neoplasm,primary mediastinal B cell lymphoma c.274C>G p.R92G 16:11255205-11255205 3
11 COSM6986929 SOCS1 haematopoietic and lymphoid tissue,mediastinum,lymphoid neoplasm,primary mediastinal B cell lymphoma c.14A>T p.N5I 16:11255465-11255465 3
12 COSM6932499 SOCS1 haematopoietic and lymphoid tissue,mediastinum,lymphoid neoplasm,primary mediastinal B cell lymphoma c.550G>A p.A184T 16:11254929-11254929 3
13 COSM6936864 RAD50 haematopoietic and lymphoid tissue,mediastinum,lymphoid neoplasm,primary mediastinal B cell lymphoma c.2443A>G p.I815V 5:132609147-132609147 3
14 COSM6936879 RAB35 haematopoietic and lymphoid tissue,mediastinum,lymphoid neoplasm,primary mediastinal B cell lymphoma c.262T>G p.Y88D 12:120099120-120099120 3
15 COSM6932496 PIM1 haematopoietic and lymphoid tissue,mediastinum,lymphoid neoplasm,primary mediastinal B cell lymphoma c.427C>A p.L143M 6:37171311-37171311 3
16 COSM6936865 PIM1 haematopoietic and lymphoid tissue,mediastinum,lymphoid neoplasm,primary mediastinal B cell lymphoma c.202C>T p.H68Y 6:37170993-37170993 3
17 COSM1581454 PIK3CD haematopoietic and lymphoid tissue,mediastinum,lymphoid neoplasm,primary mediastinal B cell lymphoma c.3061G>A p.E1021K 1:9726972-9726972 3
18 COSM6936881 PIK3C3 haematopoietic and lymphoid tissue,mediastinum,lymphoid neoplasm,primary mediastinal B cell lymphoma c.452C>T p.A151V 18:41970377-41970377 3
19 COSM6936872 PIK3C2G haematopoietic and lymphoid tissue,mediastinum,lymphoid neoplasm,primary mediastinal B cell lymphoma c.1175T>G p.L392R 12:18320999-18320999 3
20 COSM6936878 PIK3C2G haematopoietic and lymphoid tissue,mediastinum,lymphoid neoplasm,primary mediastinal B cell lymphoma c.2366C>A p.A789D 12:18424024-18424024 3
21 COSM6936875 PIK3C2G haematopoietic and lymphoid tissue,mediastinum,lymphoid neoplasm,primary mediastinal B cell lymphoma c.2105A>C p.D702A 12:18399760-18399760 3
22 COSM6929577 NTRK2 haematopoietic and lymphoid tissue,mediastinum,lymphoid neoplasm,primary mediastinal B cell lymphoma c.1912C>T p.H638Y 9:84948609-84948609 3
23 COSM6932493 MYCN haematopoietic and lymphoid tissue,mediastinum,lymphoid neoplasm,primary mediastinal B cell lymphoma c.1178G>A p.R393H 2:15945880-15945880 3
24 COSM6929580 MRE11 haematopoietic and lymphoid tissue,mediastinum,lymphoid neoplasm,primary mediastinal B cell lymphoma c.757C>T p.P253S 11:94471662-94471662 3
25 COSM6936868 KMT2C haematopoietic and lymphoid tissue,mediastinum,lymphoid neoplasm,primary mediastinal B cell lymphoma c.34C>T p.P12S 7:152435753-152435753 3
26 COSM12600 JAK2 haematopoietic and lymphoid tissue,mediastinum,lymphoid neoplasm,primary mediastinal B cell lymphoma c.1849G>T p.V617F 9:5073770-5073770 3
27 COSM6936858 JAK1 haematopoietic and lymphoid tissue,mediastinum,lymphoid neoplasm,primary mediastinal B cell lymphoma c.1208T>G p.L403W 1:64860231-64860231 3
28 COSM3410849 HIST1H3F haematopoietic and lymphoid tissue,mediastinum,lymphoid neoplasm,primary mediastinal B cell lymphoma c.191G>A p.R64H 6:26250415-26250415 3
29 COSM6932497 HGF haematopoietic and lymphoid tissue,mediastinum,lymphoid neoplasm,primary mediastinal B cell lymphoma c.1978G>T p.G660W 7:81705422-81705422 3
30 COSM6936880 FOXA1 haematopoietic and lymphoid tissue,mediastinum,lymphoid neoplasm,primary mediastinal B cell lymphoma c.1219T>C p.S407P 14:37591565-37591565 3
31 COSM6932495 FAT1 haematopoietic and lymphoid tissue,mediastinum,lymphoid neoplasm,primary mediastinal B cell lymphoma c.12674C>T p.T4225M 4:186596866-186596866 3
32 COSM6932494 FAT1 haematopoietic and lymphoid tissue,mediastinum,lymphoid neoplasm,primary mediastinal B cell lymphoma c.12674C>T p.T4225M 4:186596866-186596866 3
33 COSM6929573 FAT1 haematopoietic and lymphoid tissue,mediastinum,lymphoid neoplasm,primary mediastinal B cell lymphoma c.8456T>C p.V2819A 4:186618130-186618130 3
34 COSM6929574 FAT1 haematopoietic and lymphoid tissue,mediastinum,lymphoid neoplasm,primary mediastinal B cell lymphoma c.8456T>C p.V2819A 4:186618130-186618130 3
35 COSM37028 EZH2 haematopoietic and lymphoid tissue,mediastinum,lymphoid neoplasm,primary mediastinal B cell lymphoma c.1937A>T p.Y646F 7:148811635-148811635 3
36 COSM6936862 ERBB4 haematopoietic and lymphoid tissue,mediastinum,lymphoid neoplasm,primary mediastinal B cell lymphoma c.1904A>G p.Y635C 2:211657796-211657796 3
37 COSM231560 DNMT3A haematopoietic and lymphoid tissue,mediastinum,lymphoid neoplasm,primary mediastinal B cell lymphoma c.2206C>T p.R736C 2:25240418-25240418 3
38 COSM6986923 CDKN2B haematopoietic and lymphoid tissue,mediastinum,lymphoid neoplasm,primary mediastinal B cell lymphoma c.68C>G p.A23G 9:22008886-22008886 3
39 COSM12475 CDKN2A haematopoietic and lymphoid tissue,mediastinum,lymphoid neoplasm,primary mediastinal B cell lymphoma c.238C>T p.R80* 9:21971121-21971121 3
40 COSM6929581 CDKN1B haematopoietic and lymphoid tissue,mediastinum,lymphoid neoplasm,primary mediastinal B cell lymphoma c.322G>A p.D108N 12:12718161-12718161 3
41 COSM6929588 BCL2 haematopoietic and lymphoid tissue,mediastinum,lymphoid neoplasm,primary mediastinal B cell lymphoma c.40A>C p.I14L 18:63318627-63318627 3
42 COSM4170969 BCL2 haematopoietic and lymphoid tissue,mediastinum,lymphoid neoplasm,primary mediastinal B cell lymphoma c.4G>C p.A2P 18:63318663-63318663 3
43 COSM144522 B2M haematopoietic and lymphoid tissue,mediastinum,lymphoid neoplasm,primary mediastinal B cell lymphoma c.2T>A p.M1K 15:44711548-44711548 3
44 COSM5383384 B2M haematopoietic and lymphoid tissue,mediastinum,lymphoid neoplasm,primary mediastinal B cell lymphoma c.67+2T>C p.? 15:44711615-44711615 3
45 COSM6929579 haematopoietic and lymphoid tissue,mediastinum,lymphoid neoplasm,primary mediastinal B cell lymphoma c.757C>T p.P253S 11:94471662-94471662 3
46 COSM99935 haematopoietic and lymphoid tissue,mediastinum,lymphoid neoplasm,primary mediastinal B cell lymphoma c.404C>T p.P135L 9:21971121-21971121 3
47 COSM5383385 haematopoietic and lymphoid tissue,mediastinum,lymphoid neoplasm,primary mediastinal B cell lymphoma c.67+2T>C p.? 15:44711615-44711615 3
48 COSM3077774 haematopoietic and lymphoid tissue,mediastinum,lymphoid neoplasm,primary mediastinal B cell lymphoma c.295T>C p.C99R 6:394899-394899 3
49 COSM6936874 haematopoietic and lymphoid tissue,mediastinum,lymphoid neoplasm,primary mediastinal B cell lymphoma c.2228A>C p.D743A 12:18399760-18399760 3
50 COSM437480 haematopoietic and lymphoid tissue,mediastinum,lymphoid neoplasm,primary mediastinal B cell lymphoma c.857A>C p.E286A 17:7673763-7673763 3

Copy number variations for Primary Mediastinal B-Cell Lymphoma from CNVD:

7 (show all 32)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 16483 1 125000000 249250621 Gain Primary mediastinal b-cell lymphoma
2 37060 1 84900000 88400000 Amplification BCL10 Primary mediastinal b-cell lymphoma
3 37527 1 92000000 94700000 Amplification TGFBR3 Primary mediastinal b-cell lymphoma
4 49708 11 110400000 121200000 Gain Primary mediastinal b-cell lymphoma
5 57454 11 63400000 77100000 Gain Primary mediastinal b-cell lymphoma
6 58554 11 68400000 70400000 Loss FADD Primary mediastinal b-cell lymphoma
7 61549 12 1 35800000 Gain Primary mediastinal b-cell lymphoma
8 70078 12 58100000 67700000 Gain MDM2 Primary mediastinal b-cell lymphoma
9 77099 13 40100000 45200000 Loss Primary mediastinal b-cell lymphoma
10 88311 14 89800000 107349540 Loss Primary mediastinal b-cell lymphoma
11 89760 15 19000000 20700000 Loss Primary mediastinal b-cell lymphoma
12 106724 17 1 10700000 Loss ABR Primary mediastinal b-cell lymphoma
13 106727 17 1 10700000 Loss TUSC5 Primary mediastinal b-cell lymphoma
14 121464 18 43500000 61600000 Gain BCL2 Primary mediastinal b-cell lymphoma
15 121465 18 43500000 61600000 Gain MALT1 Primary mediastinal b-cell lymphoma
16 137935 2 154900000 169700000 Gain or amplification IL8RA Primary mediastinal b-cell lymphoma
17 137936 2 154900000 169700000 Gain or amplification IL8RB Primary mediastinal b-cell lymphoma
18 147240 2 61300000 64100000 Amplification REL Primary mediastinal b-cell lymphoma
19 147241 2 61300000 64100000 Gain or amplificatio n BCL11A Primary mediastinal b-cell lymphoma
20 157133 21 13200000 48129895 Gain Primary mediastinal b-cell lymphoma
21 172486 3 182700000 187900000 Gain BCL6 Primary mediastinal b-cell lymphoma
22 187516 4 50400000 191154276 Loss Primary mediastinal b-cell lymphoma
23 195325 5 15000000 18400000 Amplification Primary mediastinal b-cell lymphoma
24 211275 6 32548521 32557528 Loss Primary mediastinal b-cell lymphoma
25 228595 7 77500000 98000000 Amplification CDK6 Primary mediastinal b-cell lymphoma
26 230112 7 98000000 107400000 Gain Primary mediastinal b-cell lymphoma
27 233698 8 12700000 19000000 Loss Primary mediastinal b-cell lymphoma
28 233886 8 128753680 129113499 Gain MYC Primary mediastinal b-cell lymphoma
29 244977 9 1 9000000 Amplification PDL2 Primary mediastinal b-cell lymphoma
30 244983 9 1 9000000 Gain Primary mediastinal b-cell lymphoma
31 244986 9 1 9000000 Gain or amplificatio n JAK2 Primary mediastinal b-cell lymphoma
32 247560 9 130300000 141213431 Gain Primary mediastinal b-cell lymphoma

Expression for Primary Mediastinal B-Cell Lymphoma

Search GEO for disease gene expression data for Primary Mediastinal B-Cell Lymphoma.

Pathways for Primary Mediastinal B-Cell Lymphoma

Pathways related to Primary Mediastinal B-Cell Lymphoma according to GeneCards Suite gene sharing:

(show all 27)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.55 KRAS NFKBIE PTPN1 REL TNFAIP3
2
Show member pathways
12.33 KRAS NFKBIE REL TNFAIP3
3
Show member pathways
12.26 KRAS PTPN1 REL
4
Show member pathways
12.19 KRAS NFKBIE SPI1
5
Show member pathways
12.19 KRAS NFKBIE REL
6 12.18 KRAS SPI1 XPO1
7
Show member pathways
12.16 KRAS NFKBIE REL STAT6
8
Show member pathways
12.14 KRAS NFKBIE REL
9
Show member pathways
12.13 NFKBIE REL STAT6
10
Show member pathways
12.09 BCL6 KRAS NFKBIE REL
11
Show member pathways
12.06 KRAS NFKBIE STAT6
12
Show member pathways
12.04 NFKBIE REL TNFAIP3
13
Show member pathways
12.03 BCL6 KRAS REL
14 11.96 BCL6 REL SPI1
15
Show member pathways
11.91 KRAS NFKBIE REL
16
Show member pathways
11.86 KRAS NFKBIE REL
17
Show member pathways
11.83 BCL6 KRAS NFKBIE REL
18 11.68 AICDA BCL6 NFKBIE REL SPI1 STAT6
19
Show member pathways
11.63 NFKBIE REL STAT6
20
Show member pathways
11.33 NFKBIE REL
21 11.3 BCL6 XPO1
22 11.25 NFKBIE REL
23
Show member pathways
11.21 PTPN1 STAT6
24 11.19 PTPN1 STAT6
25 11.09 BCL6 XPO1
26 11.06 AICDA BCL6 SPI1 STAT6
27 10.84 TNFAIP3 XPO1

GO Terms for Primary Mediastinal B-Cell Lymphoma

Cellular components related to Primary Mediastinal B-Cell Lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytoplasm GO:0005737 9.61 AICDA BCL11A KRAS NFKBIE PTPN1 REL
2 nucleus GO:0005634 9.28 AICDA BCL11A BCL6 NFKBIE REL SPI1

Biological processes related to Primary Mediastinal B-Cell Lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 negative regulation of type 2 immune response GO:0002829 9.16 BCL6 STAT6
2 negative regulation of transcription by RNA polymerase II GO:0000122 9.1 BCL11A BCL6 REL SPI1 STAT6 XPO1
3 regulation of germinal center formation GO:0002634 8.96 BCL6 TNFAIP3

Molecular functions related to Primary Mediastinal B-Cell Lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 RNA polymerase II regulatory region sequence-specific DNA binding GO:0000977 9.43 BCL6 REL STAT6
2 DNA-binding transcription factor activity GO:0003700 9.35 BCL11A BCL6 REL SPI1 STAT6
3 distal enhancer DNA-binding transcription activator activity, RNA polymerase II-specific GO:0001205 9.16 REL SPI1
4 sequence-specific DNA binding GO:0043565 9.02 BCL11A BCL6 REL SPI1 STAT6

Sources for Primary Mediastinal B-Cell Lymphoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....